Clovis Oncology (NASDAQ:CLVS) Rating Increased to Hold at ValuEngine

Clovis Oncology (NASDAQ:CLVS) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Monday, April 1st, ValuEngine reports.

Other research analysts have also recently issued reports about the company. Gabelli reaffirmed a “buy” rating on shares of Clovis Oncology in a research note on Tuesday, December 11th. HC Wainwright initiated coverage on Clovis Oncology in a research note on Wednesday, February 13th. They set a “buy” rating and a $40.00 price objective on the stock. SunTrust Banks raised their price objective on Clovis Oncology to $35.00 and gave the company a “buy” rating in a research note on Wednesday, February 27th. Zacks Investment Research raised Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, BidaskClub raised Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $43.44.

Shares of NASDAQ:CLVS traded down $0.03 during trading on Monday, hitting $19.07. 1,571,470 shares of the company were exchanged, compared to its average volume of 1,804,843. The company has a market cap of $1.00 billion, a P/E ratio of -2.70 and a beta of 2.07. Clovis Oncology has a 52-week low of $11.50 and a 52-week high of $53.90. The company has a debt-to-equity ratio of 3.93, a current ratio of 4.55 and a quick ratio of 4.34.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.20). The firm had revenue of $30.40 million during the quarter, compared to the consensus estimate of $30.46 million. Clovis Oncology had a negative return on equity of 147.39% and a negative net margin of 385.80%. The company’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.04) EPS. On average, analysts expect that Clovis Oncology will post -6.99 earnings per share for the current fiscal year.

In other Clovis Oncology news, Director James C. Blair sold 17,056 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $27.79, for a total value of $473,986.24. Following the completion of the sale, the director now directly owns 13,439 shares in the company, valued at $373,469.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lindsey Rolfe sold 1,729 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $26.13, for a total transaction of $45,178.77. Following the completion of the sale, the insider now owns 20,953 shares of the company’s stock, valued at $547,501.89. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,782 shares of company stock valued at $576,755. 10.20% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Creative Planning grew its position in Clovis Oncology by 1.1% in the 1st quarter. Creative Planning now owns 139,550 shares of the biopharmaceutical company’s stock worth $3,464,000 after purchasing an additional 1,513 shares during the period. Oppenheimer & Co. Inc. grew its position in Clovis Oncology by 69.2% in the 1st quarter. Oppenheimer & Co. Inc. now owns 28,173 shares of the biopharmaceutical company’s stock worth $699,000 after purchasing an additional 11,521 shares during the period. Hamilton Lane Advisors LLC bought a new stake in Clovis Oncology in the 1st quarter worth approximately $346,000. Virtu Financial LLC bought a new stake in Clovis Oncology in the 1st quarter worth approximately $215,000. Finally, Geode Capital Management LLC grew its position in Clovis Oncology by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 572,004 shares of the biopharmaceutical company’s stock worth $10,273,000 after purchasing an additional 39,369 shares during the period.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also: Fiduciary

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.